Literature DB >> 25663208

An idiosyncratic reaction to clopidogrel.

Aaysha Kapila1, Lovely Chhabra2, Allison Diane Locke3, Pranav Patel4, Atul Khanna5, Chakradhar M Reddy6, Mark F Young7.   

Abstract

Clopidogrel is an irreversible antiplatelet agent belonging to the thienopyridine group that acts to antagonize the adenosine diphosphate P2Y12 receptor on platelets. It thus inhibits the activation of platelet glycoprotein GPIIb/IIIa complex, which is essential for fibrinogen—platelet complex formation. Clopidogrel has widely replaced ticlopidine because of a much better clinical safety profile. Clopidogrel is a prodrug that requires hepatic activation to exert its antiplatelet effect. Hepatotoxicity with use of clopidogrel is a rare but clinically significant phenomenon. We report a case of clopidogrel-induced hepatotoxicity in an elderly white woman.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25663208      PMCID: PMC4315382          DOI: 10.7812/TPP/14-040

Source DB:  PubMed          Journal:  Perm J        ISSN: 1552-5767


  14 in total

1.  [Clopidogrel-induced hepatotoxicity].

Authors:  Juan Carlos Ramos Ramos; José Sanz Moreno; Laura Calvo Carrasco; Juan de Dios García Díaz
Journal:  Med Clin (Barc)       Date:  2003-02-08       Impact factor: 1.725

2.  [Clopidogrel probably induced hepatic toxicity].

Authors:  José Antonio Durán Quintana; Manuel Jiménez Sáenz; Antonio Ruiz Montero; Manuel Herrerías Gutiérrez
Journal:  Med Clin (Barc)       Date:  2002-06-08       Impact factor: 1.725

3.  Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting.

Authors:  T N Chau; K F Yim; N S Mok; W K Chan; V K S Leung; M F Leung; S T Lai
Journal:  Hong Kong Med J       Date:  2005-10       Impact factor: 2.227

Review 4.  Clinico-histopathological characteristics of clopidogrel-induced hepatic injury: case report and review of literature.

Authors:  Isolde Höllmüller; Sylvia Stadlmann; Ivo Graziadei; Wolfgang Vogel
Journal:  Eur J Gastroenterol Hepatol       Date:  2006-08       Impact factor: 2.566

5.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.

Authors:  Steven R Steinhubl; Peter B Berger; J Tift Mann; Edward T A Fry; Augustin DeLago; Charles Wilmer; Eric J Topol
Journal:  JAMA       Date:  2002-11-20       Impact factor: 56.272

6.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.

Authors:  S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox
Journal:  Lancet       Date:  2001-08-18       Impact factor: 79.321

7.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.

Authors:  S Yusuf; F Zhao; S R Mehta; S Chrolavicius; G Tognoni; K K Fox
Journal:  N Engl J Med       Date:  2001-08-16       Impact factor: 91.245

8.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

9.  Hepatocellular toxicity of clopidogrel: mechanisms and risk factors.

Authors:  Anja Zahno; Jamal Bouitbir; Swarna Maseneni; Peter W Lindinger; Karin Brecht; Stephan Krähenbühl
Journal:  Free Radic Biol Med       Date:  2013-06-11       Impact factor: 7.376

Review 10.  Acute hepatitis associated with clopidogrel: a case report and review of the literature.

Authors:  Raffaella Pisapia; Amina Abdeddaim; Andrea Mariano; Alessia Rianda; Laura Vincenzi; Chiara Taibi; Andrea Baiocchini; Franca Del Nonno; Gianpiero DʼOffizi
Journal:  Am J Ther       Date:  2015 Jan-Feb       Impact factor: 2.688

View more
  2 in total

1.  Modulation of miR-26a-5p and miR-15b-5p Exosomal Expression Associated with Clopidogrel-Induced Hepatotoxicity in HepG2 Cells.

Authors:  Renata C Costa de Freitas; Raul H Bortolin; Mariana B Lopes; Letícia Tamborlin; Letícia Meneguello; Vivian N Silbiger; Rosario D C Hirata; Mário H Hirata; Augusto D Luchessi; André D Luchessi
Journal:  Front Pharmacol       Date:  2017-12-12       Impact factor: 5.810

2.  Clopidogrel-Induced Severe Hepatitis: A Case Report and Literature Review.

Authors:  Hesam Keshmiri; Anuj Behal; Shawn Shroff; Charles Berkelhammer
Journal:  Case Reports Hepatol       Date:  2016-06-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.